Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses

Moxifloxacin and levofloxacin are currently recommended as empirical initial treatment options for community-acquired pneumonia (CAP) in China by clinical guidelines and widely used in clinical settings. Several clinical outcomes comparing the efficacy and safety profiles of moxifloxacin versus levo...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xiwen, Han, Yi, Jian, Yifei, Chen, Liping, Xuan, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455983/
https://www.ncbi.nlm.nih.gov/pubmed/34584913
http://dx.doi.org/10.1016/j.dib.2021.107352
_version_ 1784570779395948544
author Du, Xiwen
Han, Yi
Jian, Yifei
Chen, Liping
Xuan, Jianwei
author_facet Du, Xiwen
Han, Yi
Jian, Yifei
Chen, Liping
Xuan, Jianwei
author_sort Du, Xiwen
collection PubMed
description Moxifloxacin and levofloxacin are currently recommended as empirical initial treatment options for community-acquired pneumonia (CAP) in China by clinical guidelines and widely used in clinical settings. Several clinical outcomes comparing the efficacy and safety profiles of moxifloxacin versus levofloxacin through a meta-analysis were reported in paper ‘Clinical benefits and cost-effectiveness of moxifloxacin as initial treatment for community-acquired pneumonia: a meta-analysis and economic evaluation’. In this dataset, we aimed at investigating more clinical endpoints comparing the efficacy and safety of moxifloxacin and levofloxacin in the treatment of CAP.
format Online
Article
Text
id pubmed-8455983
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84559832021-09-27 Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses Du, Xiwen Han, Yi Jian, Yifei Chen, Liping Xuan, Jianwei Data Brief Data Article Moxifloxacin and levofloxacin are currently recommended as empirical initial treatment options for community-acquired pneumonia (CAP) in China by clinical guidelines and widely used in clinical settings. Several clinical outcomes comparing the efficacy and safety profiles of moxifloxacin versus levofloxacin through a meta-analysis were reported in paper ‘Clinical benefits and cost-effectiveness of moxifloxacin as initial treatment for community-acquired pneumonia: a meta-analysis and economic evaluation’. In this dataset, we aimed at investigating more clinical endpoints comparing the efficacy and safety of moxifloxacin and levofloxacin in the treatment of CAP. Elsevier 2021-09-14 /pmc/articles/PMC8455983/ /pubmed/34584913 http://dx.doi.org/10.1016/j.dib.2021.107352 Text en © 2021 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Data Article
Du, Xiwen
Han, Yi
Jian, Yifei
Chen, Liping
Xuan, Jianwei
Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
title Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
title_full Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
title_fullStr Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
title_full_unstemmed Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
title_short Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
title_sort data in brief of: clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: data from meta-analyses
topic Data Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455983/
https://www.ncbi.nlm.nih.gov/pubmed/34584913
http://dx.doi.org/10.1016/j.dib.2021.107352
work_keys_str_mv AT duxiwen datainbriefofclinicalbenefitsofmoxifloxacinasinitialtreatmentofcommunityacquiredpneumoniadatafrommetaanalyses
AT hanyi datainbriefofclinicalbenefitsofmoxifloxacinasinitialtreatmentofcommunityacquiredpneumoniadatafrommetaanalyses
AT jianyifei datainbriefofclinicalbenefitsofmoxifloxacinasinitialtreatmentofcommunityacquiredpneumoniadatafrommetaanalyses
AT chenliping datainbriefofclinicalbenefitsofmoxifloxacinasinitialtreatmentofcommunityacquiredpneumoniadatafrommetaanalyses
AT xuanjianwei datainbriefofclinicalbenefitsofmoxifloxacinasinitialtreatmentofcommunityacquiredpneumoniadatafrommetaanalyses

Ejemplares similares